Aldeyra Charts a Path to reproxalap NDA Resubmission Following FDA Type A Meeting
ALDX sits 79% above its 52-week low of $1.07.
Summary
Aldeyra received FDA Type A meeting minutes on reproxalap and plans a Type D meeting by end of Q3 2026 to discuss NDA resubmission, marking the first regulatory progress since the May 2026 Complete Response Letter.
Key Events · Product Development and Regulatory · ALDX
-
FDA Type A Meeting Minutes Received
Minutes from a June 10, 2026 Type A meeting with the FDA regarding reproxalap NDA resubmission for dry eye disease have been received by Aldeyra.
-
Clarification Requested
On July 15, 2026, Aldeyra requested clarification of the minutes from the FDA, signaling that questions remain about the regulatory path forward.
-
Type D Meeting Planned
A Type D meeting with the FDA to discuss NDA resubmission is expected to be requested by the end of Q3 2026.
-
First Regulatory Step Since CRL
This marks the first disclosed regulatory interaction since the May 2026 Complete Response Letter that derailed reproxalap and the AbbVie option, offering a potential path to revive the lead asset.
Analysis · ALDX · Life Sciences
Aldeyra has received FDA meeting minutes and is advancing plans to resubmit reproxalap, including a Type D meeting by the end of Q3 2026. This represents the first concrete regulatory step since the devastating Complete Response Letter in May 2026, which wiped out the AbbVie option and triggered a securities lawsuit. The market will view any path to resubmission as a potential lifeline for the company's lead asset, though the FDA's stance remains unclear pending clarification.
At the time of this filing, ALDX was trading at $1.92 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $115.8M. The 52-week trading range was $1.07 to $6.18. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.